Florida Mental Health Institute, University of South Florida, Tampa, USA.
Community Ment Health J. 2010 Dec;46(6):523-30. doi: 10.1007/s10597-009-9288-2. Epub 2010 Jan 23.
We studied trends in antipsychotic polypharmacy over a 4 year period in order to see if a change occurred when a statewide quality improvement program aimed at reducing the practice was implemented. Antipsychotic polypharmacy prevalence rates were calculated for eight 6-month periods for enrollees with schizophrenia and schizoaffective disorder and for those with all other diagnoses. Prevalence increased from 1/2003 to 12/2004 and then declined for 4 successive 6 month periods beginning in the 1/2005-6/05 period when the program began. Piecewise linear regression results for both diagnostic groups confirmed that the change in the likelihood of antipsychotic polypharmacy during the four 6 month periods before program implementation were significantly different than during the four 6 month periods following implementation. While it is impossible to control for the effects of all variables in evaluating the impact of any system wide intervention the data suggest that the program did help to reduce the use of antipsychotic polypharmacy.
我们研究了在一个 4 年的时间段内抗精神病药联合用药的趋势,以了解当实施一项旨在减少这种做法的全州范围的质量改进计划时是否发生了变化。我们计算了患有精神分裂症和分裂情感障碍的患者和其他所有诊断患者的八个 6 个月时间段的抗精神病药联合用药患病率。患病率从 2003 年 1 月至 2004 年 12 月上升,然后在 2005 年 1 月至 6 月期间(即该计划开始时)连续 4 个 6 个月期间下降。两个诊断组的分段线性回归结果均证实,在实施该计划之前的四个 6 个月期间和之后的四个 6 个月期间,抗精神病药联合用药的可能性发生了显著变化。虽然在评估任何系统范围的干预措施的影响时,不可能控制所有变量的影响,但数据表明该计划确实有助于减少抗精神病药联合用药的使用。